

Editor

Leo van de Putte (Nijmegen)

Associate editors

Thomas Bardin (Paris)
Johannes Bijlsma (Utrecht)
Gerd Burmester (Berlin)
Bevrah Hahn (Los Angeles)
Frank Wollheim (Lund)
Anthony Woolf (Truro)

Methodological adviser

Paco Welsing (Nijmegen)

Editorial board

Martin Aringer (Vienna)
Paul Bacon (Birmingham)
Francis Berenbaum (Paris)
Maarten Boers (Amsterdam)
Dimitrios Boumpas (Heraklion)
Barry Bresnihan (Dublin)
Hillary Capell (Glasgow)
Maurizio Cutolo (Genova)
Gary Firestein (La Jolla San Diego)
Philippe Goupille (Tours)
Ellen Gravallese (Boston)
Wolfgang Gross (Bad Bramstedt)
Francis Guillemain (Nancy)
Gabriel Herrero-Beaumont (Madrid)
Frederic Houssiau (Brussels)
Tom Huizinga (Leiden)
Christian Jorgensen (Montpellier)
George Kollias (Athens)
Tore Kvien (Oslo)
Marjatta Leirisalo-Repo (Lund)
Frank Luijten (Leuven)
Hanns-Martin Lorenz (Heidelberg)

W Maslinski (Poland)
Marco Matucci Cerinic (Florence)
Kusuki Nishioka (Kanagawa)
Seza Özen (Ankara)
Thomas Pap (Magdeburg)
Eliseo Pascual Gómez (Alicante)
Leonardo Punzi (Padova)
Lars Rönnblom (Uppsala)
Blaž Rozman (Ljubljana)
Georg Schett (Vienna)
José Da Silva (Coimbra)
Hendrik Schulze-Koops (Erlangen)
Alex So (Lausanne)
Tuulikki Sokka (Nashville)
Deborah Symmons (Manchester)
Paul-Peter Tak (Amsterdam)
Alan Tyndall (Basel)
Athanasios Tzioufas (Athens)
Jiří Vencovsky (Praag)
Michael Ward (Bethesda)
Michael Weisman (Los Angeles)
Hasan Yazici (Istanbul)
Editor, *BMJ*

Advisory committee

Wim vd Berg (Nijmegen)
Stefano Bombardieri (Pisa)
Ferdinand Breedveld (Leiden)
Leslie Crofford (Michigan)
Jean-Michel Dayer (Geneva)
Mike Doherty (Nottingham)
Maxime Dougados (Paris)
John Edmonds (Sydney)
Paul Emery (Leeds)
Daniel Furst (Seattle)
Steffen Gay (Zurich)
Joachim Kalden (Erlangen)
Edward Keystone (Toronto)
Lars Klareskog (Stockholm)

Peter Lipsky (Dallas)
Stefan Lohmander (Lund)
Ravinder Maini (London)
Emilio Martin Mola (Madrid)
Haralampos Moutsopoulos (Athens)
James O'Dell (Omaha)
Karel Pavelka (Prague)
Josef Rovensky (Piestany)
Yehuda Shoenfeld (Tel-Hashomer)
Josef Smolen (Vienna)
Walther van Venrooy (Nijmegen)
Eric Veys (Gent)
Allan Wiik (Denmark)

Instructions to authors

All papers must be submitted via BenchPress at <http://submit-ard.bmjournals.com/>

Subscription information


See IFC

Copyright

© 2005 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at www.annrheumdis.com/misc/fora.shtml

- *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by MPG Books, Bodmin
- Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Hands of a patient with psoriatic arthritis, showing the characteristic skin and nail changes of psoriasis, as well as the articular and periarticular swelling for which psoriatic arthritis is known. Courtesy of A Kavanaugh, MD.

Prologue

- ii1 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) *P J Mease, D D Gladman, G G Krueger*

Psoriatic arthritis and psoriasis: classification, clinical features, pathophysiology, immunology, genetics

- ii3 Classification and diagnostic criteria for psoriatic arthritis *P S Helliwell, W J Taylor*
- ii9 Seronegative spondyloarthropathies: to lump or split? *P Nash, P J Mease, J Braun, D van der Heijde*
- ii14 Psoriatic arthritis: epidemiology, clinical features, course, and outcome *D D Gladman, C Antoni, P Mease, D O Clegg, P Nash*
- ii18 Psoriasis: epidemiology, clinical features, and quality of life *R G B Langley, G G Krueger, C E M Griffiths*
- ii24 Discussion: Clinical features, epidemiology, classification criteria, and quality of life in psoriasis and psoriatic arthritis *D D Gladman*
- ii26 Immunopathology of psoriasis and psoriatic arthritis *D J Veale, C Ritchlin, O FitzGerald*
- ii30 Psoriasis pathophysiology: current concepts of pathogenesis *J G Krueger, A Bowcock*
- ii37 Genetic epidemiology of psoriasis and psoriatic arthritis *P Rahman, J T Elder*
- ii40 Discussion: Immunology, cellular pathology, genetics *C Ritchlin*

Assessment: domains and instruments

- ii42 Science of assessment *N Bellamy*
- ii46 Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis *A Kavanaugh*
- ii49 Psoriatic arthritis assessment tools in clinical trials *P J Mease, C E Antoni, D D Gladman, W J Taylor*
- ii55 Psoriatic arthritis and imaging *P A Ory, D D Gladman, P J Mease*
- ii58 Imaging the joint and entheses: insights into pathogenesis of psoriatic arthritis *D McGonagle*
- ii61 Psoriatic arthritis imaging: a review of scoring methods *D van der Heijde, J Sharp, S Wassenberg, D D Gladman*
- ii65 Psoriasis assessment tools in clinical trials *S R Feldman, G G Krueger*
- ii69 Discussion: Assessment of psoriatic arthritis *P J Mease with contributions from F Behrens, W-H Boehncke, S R Feldman, O FitzGerald, D D Gladman, P S Helliwell, P Nash, I Olivieri, W J Taylor, P-P Tak*

.....
**Psoriatic arthritis and psoriasis:
 treatment**

- ii74 Psoriatic arthritis therapy: NSAIDs and traditional DMARDs *P Nash, D O Clegg*
- ii78 Psoriatic arthritis treatment: biological response modifiers *P J Mease, C E Antoni*
- ii83 Psoriasis treatment: traditional therapy *M Lebwohl, P T Ting, J Y M Koo*
- ii87 Psoriasis treatment: current and emerging directed therapies *L S Winterfield, A Menter, K Gordon, A Gottlieb*
- ii91 Discussion: Treatment of psoriatic arthritis and psoriasis *P J Mease with contributions from W-H Boehncke, D D Gladman, A Marchesoni, A Menter*
- ii93 Psoriatic arthritis and psoriasis: role of patient advocacy organisations in the twenty first century *G M Zimmerman, L M Savage, D C Chandler, M Maccarone Buonfigli*

.....
**Psoriatic arthritis and psoriasis
 clinical registries and genomics**

- ii101 Introduction/overview on clinical registries *D D Gladman, A Menter*

- ii103 Psoriatic arthritis clinical registries and genomics *D D Gladman, C Ritchlin, P S Helliwell*

- ii106 Psoriasis clinical registries, genetics, and genomics *J T Elder*

.....
**Developing assessment
 methodology in psoriatic arthritis**

- ii108 ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis? *D van der Heijde, J Braun, R Landewé, J Davis, J Sieper, S van der Linden, M Dougados*
- ii110 Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methods *W J Taylor*
- ii113 Consensus exercise on domains in psoriatic arthritis *D D Gladman*
- ii115 OMERACT 7 psoriatic arthritis workshop: synopsis *D D Gladman, V Strand, P J Mease, C Antoni, P Nash, A Kavanaugh*

.....
Epilogue

- ii117 Epilogue *D D Gladman, P Mease, J S Smolen, G G Krueger*

This supplement was made possible by unrestricted educational grants from Abbott, Amgen, Aventis, Biogen, Centocor, Genentech, Novartis, Schering-Plough, Serono, and Wyeth.